Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Cardiology

• Publication date

  2006-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.AMJCARD.2006.03.043PMID 16923452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

  2005cited by this paper
• Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial

  2003cited by this paper
• Inflammation and Atherosclerosis

  2002cited by this paper
• Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

  2001cited by this paper
• High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.

  2001cited by this paper
• Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.

  2001cited by this paper
• Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels

  2001cited by this paper
• High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.

  2001cited by this paper
• Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

  2001cited by this paper
• Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.

  2001cited by this paper
• Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.

  2001cited by this paper
• Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.

  2001cited by this paper
• C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

  2000cited by this paper
• Low-Density Lipoprotein Postsecretory Modification, Monocyte Function, and Circulating Adhesion Molecules in Type 2 Diabetic Patients With and Without Macrovascular Complications The Effect of α-Tocopherol Supplementation

  2000cited by this paper
• Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation.

  2000cited by this paper
• Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients.

  2000cited by this paper
• Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

  1999cited by this paper

• Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review

  2023cites this paper
• Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?

  2020cites this paper
• Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease.

  2016cites this paper
• Advancements in the Field of Cardiovascular Disease Pharmacogenetics

  2015cites this paper
• Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis

  2015cites this paper
• Innovative therapies in diabetes: colesevelam and bromocriptine

  2015cites this paper
• Antilipidemic Drug Therapy Today and in the Future

  2015cites this paper
• Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.

  2014cites this paper
• Gut microbiota and nuclear receptors in bile acid and lipid metabolism

  2014cites this paper
• Gut microbiota and nuclear receptors in bile acid and lipid metabolism

  2014cites this paper
• Colesevelam: a new and improved bile acid sequestrant?

  2013cites this paper
• Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond

  2013cites this paper
• BENEFICIAL EFFECTS OF INCORPORATING COLESEVELAM HYDROCHLORIDE

  2013cites this paper
• Effects of Atorvastatin on the Different Phases of Atherogenesis

  2012cites this paper
• Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action

  2012cites this paper
• Efficacy of Colesevelam on Lowering Glycemia and Lipids

  2012cites this paper
• Bile acid sequestrants: more than simple resins

  2012cites this paper
• Comparison of Efficacy of Pitavastatin and Colestimide in Japanese Patients with Diabetes Mellitus Complicated by Hyperlipidemia and Metabolic Syndrome

  2011cites this paper
• Comparison of E ffi cacy of Pitavastatin and Colestimide in Japanese Patients with Diabetes Mellitus

  2011cites this paper
• Emerging options in the treatment of dyslipidemias: a bright future?

  2011cites this paper
• Colesevelam HCl to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study

  2010cites this paper
• Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes

  2010cites this paper
• Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study.

  2010cites this paper
• Current and Emerging Therapies in Hypercholesterolemia: Focus on Colesevelam

  2010cites this paper
• Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective

  2009cites this paper
• Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol

  2009cites this paper
• Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes

  2009cites this paper
• Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

  2009cites this paper
• Concomitant Reduction in Low-Density Lipoprotein Cholesterol and Glycated Hemoglobin With Colesevelam Hydrochloride in Patients With Type 2 Diabetes: A Pooled Analysis

  2009cites this paper
• Lipid-lowering drugs acting at the level of the gastrointestinal tract.

  2009cites this paper
• CHAPTER 23 – Bile Acid Sequestrants

  2009cites this paper
• Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.

  2008cites this paper
• Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia

  2008cites this paper
• Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome.

  2008cites this paper
• Colesevelam hydrochloride: a specifically engineered bile acid sequestrant

  2008influential citation
• Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein.

  2008cites this paper
• Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins

  2008cites this paper
• LDL-C-Lowering therapy: Current and future therapeutic targets

  2008cites this paper
• Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

  2008cites this paper
• The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.

  2008cites this paper
• Reducing cardiovascular risk and managing dyslipidemia in women.

  2007cites this paper
• Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors

  2007cites this paper
• Plant sterols added to combination statin and colesevelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrations.

  2007cites this paper
• The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review

  2007cites this paper
• Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.

  2007cites this paper
• Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment

  2006cites this paper